A recent report by Endpoint News takes a look at the Institute for Clinical and Economic Review's (ICER) recent report on treatments for Duchenne muscular dystrophy. ICER reviewed Sarepta Therapeutics' eteplirsen and golodirsen, as well as PTC Therapeutics' deflazacort. The drug pricing watchdog in […]
ICER Recommends Significant Price Cut for Deflazacort
The Institute for Clinical and Economic Review (ICER) in its latest evidence report on treatments for Duchenne muscular dystrophy suggests that PTC Therapeutics' deflazacort would need to see a roughly 73 percent discount to be cost-effective. ICER in its report reviewed Sarepta Therapeutics' […]
ICER Announces Candidates for Assessments in 2020
The Institute for Clinical and Economic Review (ICER) on Tuesday, July 9, announced its preliminary list of candidates for reviews in 2020. According to a press release, the following drugs are among the possible targets for review:Luspatercept, Acceleron Pharma; Zynteglo, bluebird […]
ICER Plans Report on Acute Migraine Treatments
The Institute for Clinical and Economic Review (ICER) released a new report outlining a planned review of acute migraine treatments. According to a press release, ICER is planning to assess the following treatments:Biohaven's rimegepant; Allergan's ubrogepant; and Eli Lilly's agonist […]
ICER’s Pearson: ‘We’re the Mouse That Roared’
The Institute for Clinical and Economic Review's (ICER) founder Steven Pearson during an interview with the Boston Globe described the drug-pricing watchdog as the "mouse that roared," adding that it refuses to back down against "huge companies, huge resources, huge everything." Pearson tells the […]
ICER Releases Final Report on Siponimod for SPMS
The Institute for Clinical and Economic Review (ICER) suggested in its latest report on Novartis' siponimod for the treatment of secondary progressive multiple sclerosis (SPMS) that the drug "does not merit a unique role in therapy." According to a press release, the Midwest Comparative […]
Amgen Responds to ICER’s Request for Comment on Framework Update
Amgen in its response to the Institute for Clinical and Economic Review's (ICER) request for comment on its framework says it's important the organization take a transparent and objective approach. ICER issued a call for comments as it looks to update its 2020 Value Assessment Framework. "The […]
NPC Submits Feedback on ICER’s Request for Input
The National Pharmaceutical Council (NPC) submitted feedback to the Institute for Clinical and Economic Review's (ICER) request for comment as it looks to update its value assessment framework. NPC in its comments proposed a "collaborative and transparent model development process." "NPC also […]
ICER Plans Review of Acute Migraine Treatments
The Institute for Clinical and Economic Review (ICER) on Friday, June 7, announced plans to assess the comparative clinical effectiveness and value of acute migraine treatments. According to a press release, the organization will review Biohaven's rimegepant, Allergan's ubrogepant and Eli Lilly's […]
Report: ICER Seeing Rising Influence as Pricing Debates Continue
The Institute for Clinical and Economic Review (ICER) continues to gain traction in the drug pricing discussion as a growing number of stakeholders look to the organization for drug pricing benchmarks, according to a Managed Care magazine report. According to the report, ICER has a full slate this […]
